

Literaturverzeichnis

zum Titelthema „S2k-Leitlinie: Uterine Sarkome“, von Professor Dr. Dominik Denschlag und Professor Dr. Matthias W. Beckmann, Bayerisches Ärzteblatt 9/2017, Seite 400 ff.

1. Wittekind, C. and H.J. Meyer, *TNM-Klassifikation maligner Tumoren*. 2010, Weinheim: Wiley-VHC Verlag. 184-187.
2. Park, J.Y., et al., *The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma*. *Gynecol Oncol*, 2011. 122(2): p. 255-9.
3. Garg, G., et al., *Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes*. *Int J Gynecol Cancer*, 2010. 20(5): p. 888-94.
4. Wolfson, A.H., et al., *A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus*. *Gynecol Oncol*, 2007. 107(2): p. 177-85.
5. Cantrell, L.A., et al., *A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma*. *Gynecol Oncol*, 2012. 127(1): p. 22-6.
6. Reed, N.S., et al., *Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)*. *Eur J Cancer*, 2008. 44(6): p. 808-18.
7. Sutton, G., et al., *A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study*. *Gynecol Oncol*, 2000. 79(2): p. 147-53.
8. Galaal, K., et al., *Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma*. *Cochrane Database Syst Rev*, 2013. 2: p. CD006812.
9. Homesley, H.D., et al., *Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study*. *J Clin Oncol*, 2007. 25(5): p. 526-31.
10. Abeler, V.M., et al., *Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients*. *Histopathology*, 2009. 54(3): p. 355-64.
11. Kapp, D.S., J.Y. Shin, and J.K. Chan, *Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy*. *Cancer*, 2008. 112(4): p. 820-30.
12. Pautier, P., et al., *A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group*. *Ann Oncol*, 2013. 24(4): p. 1099-104.
13. Hensley, M.L., et al., *Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005)*. *Cancer*, 2013. 119(8): p. 1555-61.
14. Bernstein-Molho, R., et al., *Metastatic uterine leiomyosarcomas: a single-institution experience*. *Int J Gynecol Cancer*, 2010. 20(2): p. 255-60.

15. Maki, R.G., et al., *Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]*. J Clin Oncol, 2007. 25(19): p. 2755-63.
16. Barney, B., et al., *Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma?* Int J Gynecol Cancer, 2009. 19(7): p. 1232-8.
17. Einstein, M.H., et al., *Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease*. Int J Gynecol Cancer, 2008. 18(5): p. 1065-70.
18. Bai, H., et al., *Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases*. Gynecol Oncol, 2014. 132(3): p. 654-60.
19. Amant, F., et al., *Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma*. Br J Cancer, 2007. 97(9): p. 1194-9.
20. Sampath, S., et al., *The role of adjuvant radiation in uterine sarcomas*. Int J Radiat Oncol Biol Phys, 2010. 76(3): p. 728-34.
21. Dahhan, T., et al., *The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study*. Eur J Obstet Gynecol Reprod Biol, 2009. 144(1): p. 80-4.
22. Maluf, F.C., et al., *Endometrial stromal sarcoma: objective response to letrozole*. Gynecol Oncol, 2001. 82(2): p. 384-8.
23. Tanner EJ, 2012, Gynecol Oncol
24. Schick, U., et al., *Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study*. Int J Radiat Oncol Biol Phys, 2012. 82(5): p. e757-63.